Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2030

Study Completion Date

September 30, 2032

Conditions
Resected Pancreatic Adenocarcinoma
Interventions
DRUG

Gem/Nabpaclitaxel infusion

Downstaging and pathological response is empirically define as T1-2/N0/R0 status. If the anatomopathological analysis shows a lesion classified as T3-4 or N+ or R1, an adjuvant chemotherapy based on Gemcitabine with Nab Paclitaxel will be proposed for a period of 3 months.

DRUG

mFOLFIRINOX infusion

Downstaging and pathological response is empirically define as T1-2/N0/R0 status. In that setting the patients will receive mFOLFIRINOX adjuvant chemotherapy 3 months.

Trial Locations (1)

Unknown

CHU de Rouen, Rouen

All Listed Sponsors
collaborator

Partenariat de Recherche en Oncologie DIGEstive - PRODIGE

UNKNOWN

collaborator

Federation de recherche en chirurgie digestive (FRENCH)

UNKNOWN

lead

University Hospital, Rouen

OTHER